Anti-PCSK9 Drugs

Download the PDF

Now, almost two years after the Canadian launch of the first PCSK9i, actual claims experience shows that the overall impact of this drug class on the private payer market has in reality been minimal.

This can be attributed to both appropriate and responsible prescribing by clinicians as well as the effective claims management by insurers. In essence, the right patients are truly receiving these products.

Download pdf to read more.

Brought to you by: Amgen

Add a comment

Have your say on this topic! Comments that are thought to be disrespectful or offensive may be removed by our Benefits Canada admins. Thanks!

* These fields are required.
Field required
Field required
Field required